Stephan Wall
YOU?
Author Swipe
View article: Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies
Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies Open
INTRODUCTION Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker‐based workflows to assess 4R‐tauopathy (4RT) patients are currently missing. We suggest a nove…
View article: Subcortical tau is linked to hypoperfusion in connected cortical regions in 4-repeat tauopathies
Subcortical tau is linked to hypoperfusion in connected cortical regions in 4-repeat tauopathies Open
Four-repeat (4R) tauopathies are neurodegenerative diseases characterized by cerebral accumulation of 4R tau pathology. The most prominent 4R tauopathies are progressive supranuclear palsy (PSP) and corticobasal degeneration characterized …
View article: Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies
Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies Open
Purpose We hypothesized that severe tau burden in brain regions involved in direct or indirect pathways of the basal ganglia correlate with more severe striatal dopamine deficiency in four-repeat (4R) tauopathies. Therefore, we correlated …
View article: Association of Neurofilament Light Chain, [ <sup>18</sup> F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With β-Amyloid–Negative CBS
Association of Neurofilament Light Chain, [ <sup>18</sup> F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With β-Amyloid–Negative CBS Open
[18F]PI-2620 tau-PET, [18F]GE-180 TSPO-PET, and plasma-NfL show prognostic potential for clinical progression in patients with Aβ-negative CBS with probable 4-repeat tauopathy, which can be useful for clinical decision-making and stratifyi…
View article: Biomarker interplay between CSF p‐tau and <sup>18</sup>F‐PI‐2620 PET in Alzheimer’s disease and 4R‐tauopathy
Biomarker interplay between CSF p‐tau and <sup>18</sup>F‐PI‐2620 PET in Alzheimer’s disease and 4R‐tauopathy Open
Background Reliable biomarkers for detecting different abnormal tau protein isoforms between neurodegenerative diseases are currently missing. Phosphorylated tau (p‐tau) in the cerebrospinal fluid (CSF) is acknowledged as a 3/4R tau biomar…
View article: 17 Biomarker interplay between CSF p-tau and <sup>18</sup>F-PI-2620 PET in Alzheimer’s disease and 4R-tauopathy
17 Biomarker interplay between CSF p-tau and <sup>18</sup>F-PI-2620 PET in Alzheimer’s disease and 4R-tauopathy Open
Objectives Reliable biomarkers for detecting different abnormal tau protein isoforms between neurodegenerative diseases are currently missing. Phosphorylated tau (p-tau) in the cerebrospinal fluid (CSF) is acknowledged as a 3/4R tau biomar…